OH-AMERICHEM
5.4.2024 04:34:26 CEST | Business Wire | Press release
Americhem, a globally recognized designer and manufacturer of custom color masterbatch, functional additives, engineered compounds, and performance technologies, has been awarded the Silver EcoVadis Medal. EcoVadis is a globally recognized assessment platform that rates businesses' sustainability in various categories. This result places Americhem amongst the top 15% of companies assessed by EcoVadis.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240404483358/en/
Americhem has earned the EcoVadis Silver Medal for Sustainability (Graphic: Business Wire)
The EcoVadis rating also covers a broad range of non-financial management systems including Environmental, Labor and Human Rights, Ethics, and Sustainable Procurement impacts. Americhem’s CEO, John Richard states, “I want to express my deepest gratitude to every employee and partner who has played a role in helping us attain this remarkable achievement. This marks only the beginning for Americhem to set new standards, keep delivering excellence, and pushing boundaries within our sustainability goals.”
Americhem has made major steps forward in sustainability efforts over the past year. Centering a plan around Process, Product, and People has focused Americhem to hone efforts into the areas that matter most and can have the greatest impact. In terms of Process, Americhem’s Denmark plant pioneered a Cold Pounding technology that reduces energy usage by up to 85% and cuts emissions by up to 20% in comparison to conventional compounding processes. The facility is also powered solely by wind and solar energy from RECs Certified suppliers. In the United States, Americhem is recognized as an Operation Clean Sweep® member, with many sites having pledged to achieve zero resin pellet, flake, and powder loss to help keep materials out of the marine environment. In addition, Americhem's plants embrace recycling-compliant packaging, collaborating with customers for the reuse of packaging materials including plastic drums.
On the product front, Americhem has developed numerous technologies that empower customers to attain their sustainability objectives. Solution Dyeing, a technology used in the carpet and textile production processes, eliminates the need for excessive water usage and reduces carbon emissions significantly compared to traditional dyeing processes. Americhem’s flagship additive masterbatch nBalance® allows Post-Consumer Recycled (PCR) materials, which have a yellow tint, to be restored to PET PCR that visually mimics virgin PET.
Americhem recognizes the significance of creating a sustainable environment for both its employees and the communities it serves. The company has also been taking significant steps in its dedication to People Sustainability. By encompassing measures to enhance employee well-being through safety and health initiatives, fostering higher employee engagement through senior management efforts, contributing to charitable causes, and actively participating in volunteer activities, Americhem has noticed an overall increase in employee satisfaction.
Looking ahead, Americhem is committed to making bigger strides in its sustainability journey. In addition to continuous improvement in manufacturing processes, the company plans to further enhance its product portfolio to include sustainability features in most products, develop new product lines for physical and chemical recycling applications, and establish ongoing Life Cycle Assessment (LCA) and Carbon Footprint Analysis on all products.
Americhem would like to thank EcoVadis for their commitment to ensuring that companies remain conscious in their efforts toward a more sustainable future. To learn more about Americhem, please visit: www.americhem.com
About Americhem
Americhem is an innovative, technology-driven leader in the global polymer industry. Its foundation is built around delivering Performance, Solutions and Trust through close collaboration with customers. All of the company's products are backed by complete technical support that ensures quality, reliability, and value. Americhem operates 10 manufacturing plants and maintains sales offices throughout the world.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240404483358/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom